Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial.
Küçük Resim Yok
Tarih
2019
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Amer Soc Clinical Oncology
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
[Abstract Not Available]
Açıklama
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- MAY 31-JUN 04, 2019 -- Chicago, IL
Anahtar Kelimeler
[No Keywords]
Kaynak
Journal Of Clinical Oncology
WoS Q Değeri
Q1
Scopus Q Değeri
Cilt
37
Sayı
15
